RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Eastern Hepatobiliary Surgery Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorEastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07363356, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Diagnosed with primary liver cancer according to the diagnostic criteria of the primary liver cancer (e.g., Guidelines for Diagnosis and Treatment of Primary Liver Cancer), with post-operative pathological confirmation of hepatocellular carcinoma (HCC). Patients must have at least one of the following high-risk pathological features: tumor diameter >5 cm, more than 3 tumors, presence of microvascular invasion, presence of minor macrovascular invasion, or poor pathological differentiation (Grade 3/4).

    Inclusion criterion 2

  3. Liver function classified as Child-Pugh Class A or Class B with a score of 7.

    Inclusion criterion 6

  4. No radiotherapy within 12 weeks prior to the first dose of study drug.

    Inclusion criterion 5

    Diagnosed with another malignancy within 3 years prior to the first dose, except for radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone curative resection.

    Exclusion criterion 3

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 7

  6. Female subjects who are breastfeeding or pregnant.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07363356, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female, aged 18 to 70 years.
  • Diagnosed with primary liver cancer according to the diagnostic criteria of the primary liver cancer (e.g., Guidelines for Diagnosis and Treatment of Primary Liver Cancer), with post-operative pathological confirmation of hepatocellular carcinoma (HCC). Patients must have at least one of the following high-risk pathological features: tumor diameter >5 cm, more than 3 tumors, presence of microvascular invasion, presence of minor macrovascular invasion, or poor pathological differentiation (Grade 3/4).
  • The subject or their legal guardian understands and voluntarily signs the informed consent form, and is willing and able to complete the scheduled visits, treatment plan, and laboratory tests as required by the protocol.
  • Life expectancy of more than 6 months.
  • No radiotherapy within 12 weeks prior to the first dose of study drug.
  • Liver function classified as Child-Pugh Class A or Class B with a score of 7.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ and bone marrow function, defined as laboratory values meeting the following criteria within 7 days prior to randomization (without the support of blood transfusions, hematopoietic growth factors, albumin, or other corrective drugs within 14 days prior to obtaining the laboratory tests):

8.1. Hematological:

8.1. 2. Absolute Neutrophil Count (ANC) ≥1.5 × 10⁹/L

8.1. 3. Platelet count (PLT) ≥75 × 10⁹/L

8.1. 4. Hemoglobin (HGB) ≥9.0 g/dL

8.2. Hepatic:

8.2.1. Total Bilirubin (TBIL) ≤3 × Upper Limit of Normal (ULN)

8.2.2. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline Phosphatase (ALP) ≤5 × ULN

8.2.3. Serum Albumin ≥28 g/L

8.3. Renal:

8.3.1. Serum Creatinine (Cr) ≤ 1.5 × ULN or Creatinine Clearance (CCr) ≥ 50 mL/min (calculated by Cockcroft-Gault formula)

8.3.2. Urinalysis shows urine protein < 2+; if baseline urinalysis shows urine protein ≥ 2+, a 24-hour urine collection must demonstrate 24-hour urine protein quantification <1 g.

8.4. Coagulation:

8.4.1. International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN

  • For women of childbearing potential (WOCBP), a negative urine or serum pregnancy test must be confirmed within 3 days prior to receiving the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test is inconclusive, a serum pregnancy test is required. WOCBP and male subjects must agree to use adequate contraception during the observation period and for at least 8 weeks after the last dose of the study drug. A woman is considered not of childbearing potential if she is postmenopausal (≥1 year without menses) or has undergone surgical sterilization (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation). Subjects (both male and female) with risk of pregnancy must use highly effective contraception (with a failure rate of <1% per year) during the entire treatment period and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy agents).

Exclusion Criteria:

  • Uncorrectable coagulopathy or significant bleeding tendency.
  • Evidence of any concurrent malignant disease.
  • Diagnosed with another malignancy within 3 years prior to the first dose, except for radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone curative resection.
  • Requiring long-term anticoagulant or antiplatelet therapy that cannot be discontinued.
  • Presence of hepatic encephalopathy or refractory pleural effusion/ascites requiring therapeutic intervention.
  • Received other anti-tumor or systemic therapies within 2 weeks prior to enrollment, including:

6.1. Chinese herbal medicines with clear anti-tumor properties.

6.2. Chinese herbal medicines with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural effusion).

  • History of systemic treatment for active autoimmune disease or ongoing immunosuppressive therapy:

7.1. autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement) is not considered a form of systemic treatment.

7.2. Systemic corticosteroid therapy (excluding topical, nasal, inhaled, or other non-systemic routes) or any other form of immunosuppressive therapy within 7 days prior to the first study dose. The use of physiologic doses of corticosteroids (≤10 mg/day prednisone or equivalent) is permitted.

  • Severe hepatic or renal insufficiency.
  • Presence of any severe or uncontrolled systemic disease, including but not limited to:

9.1. Clinically significant, poorly controlled resting ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmias, or atrial fibrillation).

9.2. Unstable angina, congestive heart failure (New York Heart Association (NYHA) Class ≥ II).

9.3. Myocardial infarction within 6 months prior to randomization.

9.4. History of esophageal or gastric variceal bleeding within 6 months prior to enrollment.

9.5. Poorly controlled hypertension (systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg).

9.6. History of non-infectious pneumonitis requiring corticosteroid treatment within 1 year prior to the first dose, or current clinically active interstitial lung disease.

9.7. Active tuberculosis.

9.8. Active or uncontrolled infection requiring systemic therapy.

9.9. Clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction.

9.10. Decompensated liver disease, acute or chronic active hepatitis.

9.11. Unstable or active peptic ulcer disease, or patients with gastrointestinal bleeding.

9.12. Poorly controlled diabetes mellitus (fasting blood glucose >10 mmol/L).

9.13. Urinalysis showing urine protein ≥ ++ and confirmed 24-hour urine protein >1.0 g.

9.14. Uncontrolled hypercalcemia (>1.5 mmol/L ionized calcium, or calcium >12 mg/dL, or corrected serum calcium > ULN), or symptomatic hypercalcemia requiring continued bisphosphonate therapy.

9.15. Non-healing wound(s) or fracture(s).

9.16. Psychiatric disorder that compromises the ability to comply with the treatment protocol.

  • Female subjects who are breastfeeding or pregnant.
  • Assessed by the investigator as being unable or unwilling to comply with the requirements of the study protocol.
  • Known allergy to any of the study drug(s) used in this trial.

Quoted from ClinicalTrials.gov, NCT07363356, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07363356, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07363356